TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31886828

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment, n = 117)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo, n = 119)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo)
Number of subjects: 236
Study: 29505744

Group type: EXPERIMENTAL
Intervention: VR combined with functional electrical stimulation (FES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cyclic FES
Number of subjects: 48
Study: 27146819

Group type: EXPERIMENTAL
Intervention: Medially directed patellar realignment brace with supervised physiotherapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Supervised physiotherapy alone
Number of subjects: 156
Study: 24670340

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenol application
Number of subjects: 60
Study: 22211088

Group type: EXPERIMENTAL
Intervention: Simplified Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Training set
Number of subjects: 494

Group type: COMPARATOR
Intervention: Validation set
Number of subjects: 494
Study: 20453022

Group type: EXPERIMENTAL
Intervention: 5 consecutive nights of 4 hours time in bed (TIB)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Further sleep restriction (n = 27)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Increased sleep opportunity (n = 37)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control condition (10 hr TIB on all study nights, n = 9)
Number of subjects: 136
Study: 18035196

Group type: EXPERIMENTAL
Intervention: Abrupt cessation of guanfacine ER (1 mg to 4 mg over 16 days, then placebo from days 17 to 32)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Taper-down of guanfacine ER (1 mg to 4 mg over 16 days, then taper down from 3 mg to placebo over 16 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (administered daily from days 1-32)
Number of subjects: 45
Study: 15656812

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 15
Study: 12521705

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgical evacuation under general anaesthesia
Number of subjects: 200
Study: 10460041

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Iodine tincture
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Contaminated blood cultures
Number of subjects: 3851
Study: 7629322

Group type: EXPERIMENTAL
Intervention: NMAB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMAB-urea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium hypochlorite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemomechanical caries removal solutions
Number of subjects: 0
Study: 2242508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexedrine (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 12
Study: 327758

Group type: EXPERIMENTAL
Intervention: Clofibrate treatment
Number of subjects: 16
Study: 30670263

Group type: EXPERIMENTAL
Intervention: SWs causing mild pain (SW‐DP)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SWs generating moderate pain (SW‐MP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 63
Study: 28367667

Group type: EXPERIMENTAL
Intervention: 3D vision and haptic feedback in virtual reality
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without 3D vision and haptic feedback
Number of subjects: 20
Study: 27330026

Group type: EXPERIMENTAL
Intervention: Testimonial therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 24671501

Group type: EXPERIMENTAL
Intervention: Leining (10 mg/kg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 22203317

Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RX-10100 10 mg twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RX-10100 15 mg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily (severe depression subgroup)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (severe depression subgroup)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: RX-10100 5 mg twice daily (responders)
Number of subjects: 77
Study: 20101512

Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 70
Study: 18022750

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eta‐butanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HEMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (adhesive resin) after 24h water storage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (adhesive resin) after dry storage
Number of subjects: 0
Study: 15895228

Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 24
Study: 11872328

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control amino-acid drink
Number of subjects: 14
Study: 10421219

Group type: EXPERIMENTAL
Intervention: NCEP step II diet at isoweight energy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NCEP hypocaloric diet (15% less than isoweight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-fat, high-saturated-fat diet (baseline)
Number of subjects: 20
Study: 7593098

Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study: 1345041

Group type: EXPERIMENTAL
Intervention: Heliomolar
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: J&J Experimental (Adaptic II)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: P-30
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Marathon
Number of subjects: 142
Study: 6559719

Group type: EXPERIMENTAL
Intervention: PGE2-Gel without prior treatment with Betamimetica (n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mb) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ritodrine (10 mg) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clenbuterol (20 micrograms) administered 30 minutes prior to PGE2-Gel (n = 6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Gel without PGE2) (n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mb)
Number of subjects: 30
Study: 31597934

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 134
Study: 28985294

Group type: EXPERIMENTAL
Intervention: Initial outreach to 114 practices, 52 (45%) practices responded with interest.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Average time to enroll practices was 71 calendar days (range 11‐107).
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recruitment duration based on organization size (large vs small).
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recruitment barriers identified.
Number of subjects: 25
Study: 26574566

Group type: EXPERIMENTAL
Intervention: Self-Monitoring Blood Pressure (SMBP)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 224
Study: 23864514

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (vibration amplitude: 1-3 mm; frequency: 6-26 Hz; 4-5 bouts × 60 seconds; 3-5 times weekly)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care and exercises (control group)
Number of subjects: 44
Study: 23114193

Group type: EXPERIMENTAL
Intervention: Dermabond® supplementation after wound closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standardized closure without Dermabond®)
Number of subjects: 0
Study: 21859995

Group type: EXPERIMENTAL
Intervention: FLOX (FULV plus oxaliplatin 85 mg/m(2) IV on days 1, 15, and 29 of each cycle)
Number of subjects: 2409

Group type: COMPARATOR
Intervention: FULV (FU 500 mg/m(2) by IV bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-week cycle for three cycles)
Number of subjects: 2409

Group type: EXPERIMENTAL
Intervention: FLOX (FULV plus oxaliplatin)
Number of subjects: 2409

Group type: COMPARATOR
Intervention: FULV (control)
Number of subjects: 2409
Study: 19150573

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (SurePath)
Number of subjects: 86469

Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 86469
Study: 17846056

Group type: COMPARATOR
Intervention: 0-1 features of the metabolic syndrome
Number of subjects: 5522

Group type: EXPERIMENTAL
Intervention: two features of the metabolic syndrome
Number of subjects: 5522

Group type: EXPERIMENTAL
Intervention: three features of the metabolic syndrome
Number of subjects: 5522

Group type: EXPERIMENTAL
Intervention: four features of the metabolic syndrome
Number of subjects: 5522
Study: 15274382

Group type: EXPERIMENTAL
Intervention: 1-month intravenous induction of IFN-alpha2b
Number of subjects: 200

Group type: COMPARATOR
Intervention: 1 year of adjuvant IFN-alpha2b therapy
Number of subjects: 200
Study: 11418367

Group type: EXPERIMENTAL
Intervention: Early consolidation chemotherapy (C-1)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Early and delayed consolidation chemotherapy (C-1 and C-2)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard maintenance chemotherapy for 2 years
Number of subjects: 195
Study: 9564795

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1000 mg/day calcium supplement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 400 mg/day cyclical sodium etidronate with 1000 mg/day calcium
Number of subjects: 38
Study: 7753886

Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 60 min before meal (Group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 5 min before meal (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 30 min before meal (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (400 mg starch)
Number of subjects: 36
Study: 2275909

Group type: EXPERIMENTAL
Intervention: Interpleural 0.5% bupivacaine with epinephrine every six hours for a total of four injections
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group treated with systemic narcotics alone
Number of subjects: 26
Study: 6103440

Group type: EXPERIMENTAL
Intervention: 2 units of whole stored blood at transplantation
Number of subjects: 27

Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 27
Study: 31252651

Group type: EXPERIMENTAL
Intervention: Bee venom (BV)
Number of subjects: 0
Study: 28481623

Group type: EXPERIMENTAL
Intervention: Yuzu fragrance
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lavender fragrance
Number of subjects: 17
Study: 25828038

Group type: EXPERIMENTAL
Intervention: SGP‐HA (without lidocaine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 180
Study: 23706639

Group type: EXPERIMENTAL
Intervention: Albaconazole 100 mg weekly for 24 or 36 weeks
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Albaconazole 200 mg weekly for 24 or 36 weeks
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Albaconazole 300 mg weekly for 24 or 36 weeks
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Albaconazole 400 mg weekly for 24 or 36 weeks
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 21434334

Group type: EXPERIMENTAL
Intervention: Integrative medical approach (IMA)
Number of subjects: 141
Study: 19609643

Group type: EXPERIMENTAL
Intervention: Warfarin (standard dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferior vena cava filter placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17269241

Group type: EXPERIMENTAL
Intervention: CustomCornea
Number of subjects: 58

Group type: COMPARATOR
Intervention: CustomVue
Number of subjects: 58
Study: 15231854

Group type: EXPERIMENTAL
Intervention: Whisky consumption (40 g of alcohol daily for 17 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 23
Study: 11920257

Group type: EXPERIMENTAL
Intervention: Surgical group (early lung resection)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Medical group (antifungal drugs)
Number of subjects: 54
Study: 9621526

Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh repair (n = 42)
Number of subjects: 80

Group type: COMPARATOR
Intervention: modified Bassini repair (n = 38)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 80
Study: 7936512

Group type: EXPERIMENTAL
Intervention: Depot leuprolide (3.75 mg/month)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 1979687

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 0
Study: 572699

Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Krypton laser treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31714573

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Emergency admission for UC
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Period comparison 2007-2011 vs 2012-2017
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Increased comorbidity, lower deprivation, high provider volume of colectomies for UC
Number of subjects: 10051

Group type: COMPARATOR
Intervention: Female sex and Asian ethnicity
Number of subjects: 10051
Study: 31835387

Group type: EXPERIMENTAL
Intervention: Ergomotor intervention (integrated program with tailor-made motor control training and ergonomic advice for 12 weeks)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (usual care with conventional physiotherapy for 12 weeks)
Number of subjects: 101
Study: 28349271

Group type: EXPERIMENTAL
Intervention: Elaeagnus
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Elaeagnus/Boswellia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 75
Study: 25834682

Group type: EXPERIMENTAL
Intervention: US Simulator Skills Training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional Skills Training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Traditional Skills Training Plus US Simulator Skills Training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups pre- and post-course
Number of subjects: 36
Study: 23250116

Group type: EXPERIMENTAL
Intervention: 10-day probiotics regimen
Number of subjects: 115

Group type: COMPARATOR
Intervention: 7-day metronidazole regimen
Number of subjects: 115
Study: 22480099

Group type: EXPERIMENTAL
Intervention: 200 mg elemental iron once per week
Number of subjects: 100

Group type: COMPARATOR
Intervention: 100 mg elemental iron daily (group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mg elemental iron once per week (group II)
Number of subjects: 100
Study: 19440906

Group type: EXPERIMENTAL
Intervention: Stage-matched message intervention
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Generic message intervention
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (lectures only)
Number of subjects: 130
Study: 17316434

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (group programme)
Number of subjects: 0
Study: 15531624

Group type: EXPERIMENTAL
Intervention: Lottery for six bottles of champagne
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One chance of six bottles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modest incentive
Number of subjects: 0
Study: 11560881

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day for 8 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thalidomide doses greater than 100 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4
Study: 9786163

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 7943769

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 31
Study: 31313855

Group type: EXPERIMENTAL
Intervention: 12-week sexual rehabilitation programme
Number of subjects: 10
Study: 30461604

Group type: EXPERIMENTAL
Intervention: Rational Emotive Digital Storytelling (REDStory) therapy for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 80
Study: 27038001

Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ticagrelor (45, 60, and 90 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ticagrelor (45 and 90 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 36
Study: 25545196

Group type: EXPERIMENTAL
Intervention: OAS with ICAPS R(®) - Alcon Laboratories, n = 26
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: OAS without ω‐3 fatty acids (OFTAN MACULA(®) - Laboratorios Esteve, n = 28)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group without OAS, n = 63
Number of subjects: 117
Study: 24060942

Group type: EXPERIMENTAL
Intervention: Cyanotic CHD
Number of subjects: 47218

Group type: EXPERIMENTAL
Intervention: Endocardial cushion defects
Number of subjects: 47218

Group type: EXPERIMENTAL
Intervention: Left-sided lesions
Number of subjects: 47218

Group type: EXPERIMENTAL
Intervention: Cardiac surgery within 6 months
Number of subjects: 47218

Group type: EXPERIMENTAL
Intervention: Age <3 years
Number of subjects: 47218
Study: 20875492

Group type: EXPERIMENTAL
Intervention: Whole inactivated Mycobacterium vaccae (MV)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2013
Study: 18367035

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with stent placement
Number of subjects: 0
Study: 16824833

Group type: EXPERIMENTAL
Intervention: Pactimibe, 100 mg daily for 18 months
Number of subjects: 534

Group type: COMPARATOR
Intervention: Matching placebo for 18 months
Number of subjects: 534
Study: 14700149

Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 doses at 24-hour intervals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin (3 doses at 12-hour intervals)
Number of subjects: 30
Study: 11042920

Group type: EXPERIMENTAL
Intervention: Patients who received questionnaires requesting consent to collect data from clinical records.
Number of subjects: 5069

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 5069
Study: 8798051

Group type: EXPERIMENTAL
Intervention: Visipaque
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omnipaque
Number of subjects: 0

Group type: COMPARATOR
Intervention: monomeric CM
Number of subjects: 0
Study: 1633722

Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard naproxen
Number of subjects: 123
Study: 6511139

Group type: EXPERIMENTAL
Intervention: Distilled beverage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brewed beverage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (distilled)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (brewed)
Number of subjects: 60
Study: 30849533

Group type: EXPERIMENTAL
Intervention: Email completion of NDI and JOA questionnaires
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Phone completion of NDI and JOA questionnaires before in-office administration
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: In-office administration followed by phone completion of NDI and JOA
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Email versions of NDI and JOA
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Phone-before-office versions of NDI and JOA
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Office-before-phone versions of NDI and JOA
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Follow-up phone reminders for email administration of NDI and JOA
Number of subjects: 206

Group type: COMPARATOR
Intervention: Completion rates between email and in-office questionnaire completion
Number of subjects: 206

Group type: COMPARATOR
Intervention: Completion rates between phone-before-office and in-office questionnaire completion
Number of subjects: 206
Study: 29984912

Group type: EXPERIMENTAL
Intervention: Haemodynamically optimized dual chamber His‐bundle pacing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Backup pacing only (using the non‐His ventricular lead)
Number of subjects: 160
Study: 26630997

Group type: COMPARATOR
Intervention: Contrast concentration of 300 mgI/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Contrast concentration of 240 mgI/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Contrast concentration of 140 mgI/mL
Number of subjects: 60